ArticleJournal of clinical microbiology2010
Clonal analysis of colonizing group B Streptococcus, serotype IV, an emerging pathogen in the United States.
Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Genomic epidemiology of Group B Streptococcus colonization among pregnant women in Japan, 2021-2023.PloS one · 2026Article
- An opportunistic pathogen under stress: how Group B Streptococcus responds to cytotoxic reactive species and conditions of metal ion imbalance to survive.FEMS microbiology reviews · 2024Review
- Genomic Analysis of Group BOpen forum infectious diseases · 2023Article
- Comparative Analysis of the Molecular Characteristics of Group BAnnals of laboratory medicine · 2023Article
- Next Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases.Genes · 2022Review
- Evidence of Common Isolates ofFrontiers in microbiology · 2021Article
- A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.The Journal of infectious diseases · 2019Article
- Article
- Genomic Insights Into the Distribution and Evolution of Group B Streptococcus.Frontiers in microbiology · 2019Review
- Genomic characterisation of perinatal Western Australian Streptococcus agalactiae isolates.PloS one · 2019Article
- Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets.Clinical microbiology reviews · 2018Review
- Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology.Frontiers in microbiology · 2018Review
- Identification of Group B Streptococcus Capsule Type by Use of a Dual Phenotypic/Genotypic Assay.Journal of clinical microbiology · 2017Article
- Serotype Distribution, Population Structure, and Antimicrobial Resistance of Group B Streptococcus Strains Recovered from Colonized Pregnant Women.Journal of clinical microbiology · 2017Article
- Streptococcus agalactiae Serotype IV in Humans and Cattle, Northern EuropeEmerging infectious diseases · 2016Article
- Serotype IV Sequence Type 468 Group B Streptococcus Neonatal Invasive Disease, Minnesota, USA.Emerging infectious diseases · 2016Article
- Streptococcus agalactiae from pregnant women: antibiotic and heavy-metal resistance mechanisms and molecular typing.Epidemiology and infection · 2016Article
- Serotype IV Streptococcus agalactiae ST-452 has arisen from large genomic recombination events between CC23 and the hypervirulent CC17 lineages.Scientific reports · 2016Article
- Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013.Journal of clinical microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colonizing group B Streptococcus (GBS) capsular polysaccharide (CPS) type IV isolates were recovered from vaginal and rectal samples obtained from 97 (8.4%) nonpregnant women of 1,160 women enrolled in a U.S. multicenter GBS vaccine study from 2004 to 2008. Since this rate was much higher than the rate of prevalence of 0.4 to 0.6% that we found in previous studies, the isolates were analyzed by using surface protein profile identification, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) to characterize them and identify trends in DNA clonality and divergence. Of the 101 type IV isolates studied, 53 expressed alpha and group B protective surface (BPS) proteins, 27 expressed BPS only, 20 expressed alpha only, and 1 had no detectable surface proteins. The isolates spanned three PFGE macrorestriction profile groups, groups 37, 38, and 39, of which group 37 was predominant. The isolates in group 37 expressed the alpha and BPS proteins, while those in groups 38 and 39 expressed the alpha protein only, with two exceptions. MLST studies of selective isolates from the four protein profile groups showed that isolates expressing alpha,BPS or BPS only were of a new sequence type, sequence type 452, while those expressing alpha only or no proteins were mainly of a new sequence type, sequence type 459. Overall, our study revealed a limited diversity in surface proteins, MLST types, and DNA macrorestriction profiles for type IV GBS. There appeared to be an association between the MLST types and protein expression profiles. The increased prevalence of type IV GBS colonization suggested the possibility that this serotype may emerge as a GBS pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.